戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nts with idiopathic scleritis and those with herpes infection.
2 ccurately diagnose anogenital lesions due to herpes infection.
3 significance of HS and 3-OS HS during ocular herpes infection.
4 D) contribute to protective immunity against herpes infection.
5 d, these cells protect hosts against genital herpes infection.
6 en (36 percent) had symptoms consistent with herpes infection.
7 al morbidity or with any cases of congenital herpes infection.
8 e seropositive reported a history of genital herpes infection.
9 silon), which protects against chlamydia and herpes infection.
10 nal inflammation in a mouse model of genital herpes infection.
11 press replication or reactivation of chronic herpes infections.
12 against primary and secondary female genital herpes infections.
13 cornea and TG, the sites of acute and latent herpes infections.
14 n global estimates of the number of neonatal herpes infections.
15 ]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-repo
16 vaccine formulation that could combat ocular herpes infection and disease in humans.
17 dependent protective immunity against ocular herpes infection and disease.
18 B)-specific CD8(+) T cells protect mice from herpes infection and disease.
19  a strong protective immunity against ocular herpes infection and disease.
20 dependent protective immunity against ocular herpes infection and disease.
21  epitope (gB498-505), protect against ocular herpes infection and disease.
22 ective immunity against sexually transmitted herpes infection and disease.
23 epitope-based vaccine against primary ocular herpes infection and disease.
24 onses, associated with a reduction in ocular herpes infection and disease.
25 D T-cell epitopes protected mice from ocular herpes infection and disease.
26 associated with protection against recurrent herpes infection and disease.
27 ated with a significant reduction in corneal herpes infection and disease.
28 as associated with protection against ocular herpes infection and disease.
29 eutic strategies to treat blinding recurrent herpes infection and disease.
30 ated with protective immunity against ocular herpes infection and disease.IMPORTANCE We report that n
31 hree cases each of hypersensitivity and oral herpes infection and one case of herpes zoster infection
32 tiviral CD8(+) T cell exhaustion during SYMP herpes infection and pave the way to targeting immune ch
33 ory tract infection, and to a lesser degree, herpes infection and selected laboratory abnormalities.
34 mate the prevalence and incidence of genital herpes infection and to assess the relation between HSV-
35                                              Herpes infections are among the most common sexually tra
36                                              Herpes infections are among the most common sexually tra
37 rvix and ectocervix/vagina) to mimic genital herpes infections caused by herpes simplex virus types 1
38 e infection (HR = 1.35, 95% CI = 1.07-1.69), herpes infection (herpes simplex, HR = 1.64, 95% CI = 1.
39 ncreased risk of PTD associated with genital herpes infection if left untreated and a potential benef
40 effective for blocking the spread of topical herpes infection in an animal model.
41 ive for the suppression of recurrent genital herpes infection in HIV-infected individuals.
42 thophysiological features typical of genital herpes infection in humans, including the production of
43                          Here, using genital herpes infection in mice, we show that primary infection
44 ucosa and provide protection against genital herpes infection in mice.
45 can provide passive immunity against genital herpes infections in mice; orally administered polymeric
46 utinely used for topical treatment of ocular herpes infections in the United States.
47                                     Neonatal herpes infection is uncommon yet can result in substanti
48 caused by HSV-2, which suggests that genital herpes infection likely increases the efficiency of the
49 ications in mitigating the effect of genital herpes infection on the risk of PTD.
50 ma, iron or nutrient starvation, concomitant herpes infection, or maturation of the host cell into it
51 cation of Disease, Tenth Revision, codes for herpes infection: P35.2, B00.0-B00.9, and A60.0-A60.9.
52 tric infectious diseases concerning neonatal herpes infections, poliovirus immunization schedule, and
53  (16%) patients treated with alemtuzumab had herpes infections (predominantly cutaneous) compared wit
54               Importance: Current therapy of herpes infections relies on nucleoside analogues.
55  has been shown to protect mice from genital herpes infection, the mechanism by which these agents pr
56       In diseases such as diabetes, HIV, and herpes infections, the resultant neuropathic pain is oft
57              Interestingly, during an ocular herpes infection, there was a selective increase in the
58 he proportion of HSV-1 among initial genital herpes infections was higher among men who had sex with
59               Using a mouse model of genital herpes infection, we demonstrate that both antibodies an
60 nes, key questions for management of genital herpes infection were developed with a panel of experts.
61 upper respiratory tract infections, and oral herpes infections were more frequent with ocrelizumab th
62                                     Neonatal herpes infection, while uncommon, can result in substant
63              A vaccine that prevents genital herpes infection will have major public health benefits.